S.G. Power to rebrand as Crestwell Healthcare, enter pharmaceutical business

Shareholders of S.G. Power Limited have approved a series of resolutions to transform the company into a healthcare and pharmaceutical-focused business, including changing its name to Crestwell Healthcare Limited, altering its business objectives and increasing its authorised capital to ₨800 million.

The resolutions were passed during an Extraordinary General Meeting held on May 13, 2026, according to a notice submitted to the Pakistan Stock Exchange on Thursday.

Under the approved resolutions, the company will seek regulatory approval from the Securities and Exchange Commission of Pakistan (SECP) to change its name from S.G. Power Limited to Crestwell Healthcare Limited.

The company also authorised its chief executive officer to adopt an alternative name if the proposed name is unavailable.

As part of the restructuring, shareholders approved amendments to the company’s Memorandum of Association to shift its principal line of business toward healthcare and pharmaceuticals.

According to the revised object clause, the company plans to engage in importing, manufacturing, marketing, distribution, trading and maintenance of medical equipment, instruments, devices and hospital supplies.

The amended business scope also includes manufacturing and trading pharmaceutical, medicinal and chemical products, including vitamin preparations and healthcare-related products used for treatment and health promotion.

The company said the strategic transformation was aimed at repositioning the business as a healthcare-focused platform with primary emphasis on the pharmaceutical sector.

Shareholders also approved the relocation of the company’s registered office from Sindh to Punjab.

In another major decision, the company approved an increase in authorised share capital from ₨200 million to ₨800 million.

The authorised capital will now consist of 80 million ordinary shares with a face value of ₨10 each, compared to the previous 20 million shares.

The company further authorised its board of directors to explore strategic partnerships, including distribution agreements, licensing arrangements, joint ventures and commercial collaborations with local and foreign pharmaceutical and healthcare entities.

Shareholders also allowed the company, subject to regulatory approvals, to establish or invest in subsidiaries, associated companies, branch offices and special purpose vehicles in Pakistan and abroad for operational and strategic purposes.

The company authorised its chief executive officer, directors and company secretary to complete all regulatory filings and corporate formalities related to the implementation of the approved resolutions.